Characterization of the gene expression profile in younger and older low-grade glioma patients

RNA-seq dataset

RNA-seq expression data and corresponding clinical data of 504 primary low-grade glioma patients were obtained from The Cancer Genome Atlas (https://gdc.cancer.gov/about-data/publications/pancanatlas) [8]. The expression matrix of Fragments per Kilobase of transcript per Million mapped reads (FPKM) was normalized by upper quartile which the FPKM value was divided by the 75th percentile value for the samples. Then, the matrix was transformed to log2-scale.

Gene-expression signatures

Gene expression signatures were obtained from literature. For each signature, we calculated the average expression of the member genes with the normalized RNA-seq data and transformed to z-score across all cases. We compared the expression of each signature between young versus older cases. Fold change and Mann-Whitney test p-value were calculated. The false discovery rate (FDR) for multiple comparison adjustment was calculated using the Benjamini Hochberg algorithm.

Differentially expressed genes

To identify differentially expressed genes, we calculated fold change and t-test p-value for each gene between younger and older cases. Differentially expressed genes were defined as fold change ≥ 1.50 or ≤ 0.67 with Benjamini Hochberg corrected false discovery rate (FDR)□<□0.05. In this analysis, we included 20,282 human genes which are available in the TCGA RNA-seq dataset.

Gene set enrichment analysis

The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway was used to perform enrichment analysis. P value was generated by Fisher’s exact test using the “clusterProfiler” package in R.

Gene-expression signatures

We constructed six gene-signatures (Supplementary Table1) including one proliferation signature (Mitosis Kinase Score, MKS) [9] five immune cell signatures (e.g. T Cell, B Cell, Mast Cell, Dendritic Cell [10], and Tumor inflammation signature (TIS) [11]. Metabolic genes were obtained from NanoString Technology. For each signature, we calculated the average normalized expression of the member genes and transformed to z-score across all cases in a given cohort.

Statistical analysis

Fold change and Student’s t-test was used for differential expression analysis. Mann-Whitney test was used to compare the expression of signatures. All statistical tests were two-sided and FDR for multiple comparisons was calculated using the Benjamini Hochberg algorithm. FDR

< 0.05 was considered significant. All analyses were performed in R version 3.6.1.

Study design

We collected the RNA-seq data of 504 low-grade-glioma patients separating patients into two groups: younger (age below 50 years) and older patients (age more than 50 years). We further performed differential expression analysis and pathway enrichment analysis to characterize the gene expression differences between the two groups. Finally, we compare metablic and immune gene expression between the younger patients and older patients (Figure 1).

• Download figure
• Open in new tab

Figure 1. Schema of study design.

Differentially expressed genes

To characterize the age-related gene-expression alterations, we performed differential expression analysis between younger and older patients’ LGG tissues. We identified 892 up-regulated genes and 1481 down-regulated genes by comparing the expression profiles of 20,282 human coding genes between younger versus older LGG (Figure 2). Genes such as ESX1, PRSS35, SFRP2, TPTE22, MKX, IRX2, and PCDH15 were significantly overexpressed (fold change > 1.5) in younger patients, while genes such as ETV4, SPRY4, RIN1, EN1, CHI3L1, and TBX5 were down-regulated (fold change <1.5) in younger patients.

• Download figure
• Open in new tab

Figure 2. The differentially expressed genes between younger versus older patients in LGG.

Volcano plots indicate the fold change (FC) and FDR of differentially expression analysis. P-values were generated by Student’s t-test and corrected by Benjamini Hochberg FDR. Red dots indicated genes meet criteria of |log2 fold change| ≥ 0.585 and FDR < 0.05 (significant), and other genes were marked as grey (none, not significant). Top DEGs with |log2 fold change| > 0.585 and FDR < 1e-05 were labeled with official gene symbols.

Pathway enrichment analysis

The differentially expressed genes were significantly enriched in 7 KEGG pathways, including protein digestion and absorption, transcriptional misregulation in cancer, ECM-receptor interaction, neuroactive ligand-receptor interaction, amoebiasis, cytokine-cytokine receptor interaction, and complement and coagulation cascades pathways (FDR < 0.05) (Figure 3).

• Download figure
• Open in new tab

Figure 3. The pathway enrichment analysis of differentially expressed genes.

Pathway enrichment p-values were generated by the Fisher’s exact-test and adjusted by Benjamini Hochberg for multiple comparisons. Color indicates the adjusted p value. X-axis indicates the number of differentially expressed genes involved in each pathway. Y-axis indicates the name of enriched KEGG pathways.

Cancer-related metabolic gene expression in younger versus older LGG patients

We further examined the metabolic gene expression signatures compared between younger and older groups. The gene signatures were defined as the mean of average normalized expression of the member genes and transformed to z-score (Supplementary Table 1). Eleven metabolic signatures were lower expressed in the younger groups compared to the older group, e.g., the nucleotide synthesis, KEAP1 NRF2, and mTOR signatures, while two signatures (autophagy and mTOR) were up-regulated in the younger patients (FDR = 1.21×10-4) (Table 1). The mTOR and autophagy genes are upregulated in younger patients while others are down regulated.

Cancer-related immune gene expression in younger versus older LGG patients

We finally investigated the MKS proliferation and six immune gene signatures in younger versus older patients including TIS, T Cell, B Cell, Dendritic Cell, and Mast Cell. MKS, TIS, and T Cell signatures are down regulated in young LGG patients while are up regulated in older LGG patients (Table 2, FDR<0.02). The results suggest LGG in older patients have higher proliferation activity and immune activity than young patients.